CRSP logo

CRSP
CRISPR Therapeutics AG

41,710
Mkt Cap
$5.11B
Volume
3,326.00
52W High
$78.48
52W Low
$30.04
PE Ratio
-8.16
CRSP Fundamentals
Price
$53.17
Prev Close
$53.07
Open
$53.00
50D MA
$54.33
Beta
1.57
Avg. Volume
1.84M
EPS (Annual)
-$6.47
P/B
2.65
Rev/Employee
$8,931.30
$2,938.96
Loading...
Loading...
News
all
press releases
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks·1d ago
News Placeholder
More News
News Placeholder
What is Brookline Cap M's Estimate for CRSP Q1 Earnings?
CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Brookline Cap M issued their Q1 2026 earnings per share estimates for CRISPR Therapeutics in a report released on Thursday, February 12th...
MarketBeat·2d ago
News Placeholder
Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)
Key PointsCRISPR Therapeutics' fourth quarter was relatively disappointing...
Nasdaq News: Markets·5d ago
News Placeholder
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.
Zacks·5d ago
News Placeholder
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 8% on Analyst Upgrade
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 8% Following Analyst Upgrade...
MarketBeat·5d ago
News Placeholder
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates
CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.
Zacks·5d ago
News Placeholder
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $82.00
Needham & Company LLC raised their price objective on CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a "buy" rating in a research note on Friday...
MarketBeat·5d ago
News Placeholder
CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) posted its earnings results on Thursday. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.16...
MarketBeat·6d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -18.85% and -78.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
CRISPR Therapeutics Earnings Report: Q4 Overview
read more...
Benzinga·6d ago
<
1
2
...
>

Latest CRSP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.